The company is developing a platform of drugs that increase the amount of oxygen in the blood and tissues to treat life threatening conditions. The Initial focus is cancer patients treated with radiotherapy. Phase Ib/II clinical trials are in progress for the platform first drug that has shown therapeutic reversal of tumor hypoxia and evidence of improved survival. They have received orphan drug designation from the US FDA for glioblastoma multiforme and also for sickle cell disease. The company has approved IND’s for stroke and sickle cell disease. The stroke trial is in progress.

Posted Oct 17, 2016

Did you know that social networking is a great way to buy a business? Sign up now and we'll show you how.

By clicking "Sign Up" you confirm that you accept the Terms of Use and Privacy Policy, including cookie use.

Disclaimer: MergerNetwork has not independently verified any of the information in this listing and makes no warranty as to its accuracy or completeness.